The COP-BLAM programs

evolving chemotherapy concepts in large cell lymphoma.

M. Coleman, James Olen Armitage, M. Gaynor, D. McDermott, D. D. Weisenburger, K. Adler, M. Beshevkin, R. T. Silver, A. M. Reisman, M. W. Pasmantier

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine (COP-BLAM) programs of combination chemotherapy were administered to patients with advanced diffuse large cell lymphoma. The original COP-BLAM programs were designed to deliver intense multidrug therapy maximizing tumor kill. COP-BLAM programs IA and IB, easily administered on an outpatient basis, produced identical 73% complete remissions (CRs) and 55% long-term, disease-free survival (DFS). COP-BLAM III, an outgrowth of studies using infusional therapy, differed from COP-BLAM by using infusional bleomycin and vincristine alternated with bolus vincristine. With COP-BLAM III, 84% CRs, 76% "potential cures," and a 65% DFS were produced at a median follow-up time of 50 months. COD-BLAM IV, using four sequential cycles of infusional chemotherapy, high-dose alternating myelosuppressives (doxorubicin, cyclophosphamide), and cycle-active agents (methotrexate, cytarabine, and etoposide) produced 88% CRs, 67% potential cures, and a 64% DFS at a median follow-up of 24 months. COP-BLAM V employs four to six sequential cycles of infusional chemotherapy tailored to the rapidity of response. Preliminary results in patients with high-risk Hodgkin's disease suggest COP-BLAM V may be effective despite the shortened treatment time. In all programs, prognostic factors were critical determinants in the results achieved, particularly age and rapidity of response.

Original languageEnglish (US)
Pages (from-to)23-33
Number of pages11
JournalSeminars in hematology
Volume25
Issue number2 Suppl 2
StatePublished - Jan 1 1988

Fingerprint

Vincristine
Disease-Free Survival
Lymphoma
Bleomycin
Drug Therapy
Doxorubicin
Cyclophosphamide
Procarbazine
Lymphoma, Large B-Cell, Diffuse
Cytarabine
Etoposide
Prednisone
Combination Drug Therapy
Hodgkin Disease
Methotrexate
Outpatients
Therapeutics
Neoplasms
COP-BLAM protocol

ASJC Scopus subject areas

  • Hematology

Cite this

Coleman, M., Armitage, J. O., Gaynor, M., McDermott, D., Weisenburger, D. D., Adler, K., ... Pasmantier, M. W. (1988). The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma. Seminars in hematology, 25(2 Suppl 2), 23-33.

The COP-BLAM programs : evolving chemotherapy concepts in large cell lymphoma. / Coleman, M.; Armitage, James Olen; Gaynor, M.; McDermott, D.; Weisenburger, D. D.; Adler, K.; Beshevkin, M.; Silver, R. T.; Reisman, A. M.; Pasmantier, M. W.

In: Seminars in hematology, Vol. 25, No. 2 Suppl 2, 01.01.1988, p. 23-33.

Research output: Contribution to journalArticle

Coleman, M, Armitage, JO, Gaynor, M, McDermott, D, Weisenburger, DD, Adler, K, Beshevkin, M, Silver, RT, Reisman, AM & Pasmantier, MW 1988, 'The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma.', Seminars in hematology, vol. 25, no. 2 Suppl 2, pp. 23-33.
Coleman M, Armitage JO, Gaynor M, McDermott D, Weisenburger DD, Adler K et al. The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma. Seminars in hematology. 1988 Jan 1;25(2 Suppl 2):23-33.
Coleman, M. ; Armitage, James Olen ; Gaynor, M. ; McDermott, D. ; Weisenburger, D. D. ; Adler, K. ; Beshevkin, M. ; Silver, R. T. ; Reisman, A. M. ; Pasmantier, M. W. / The COP-BLAM programs : evolving chemotherapy concepts in large cell lymphoma. In: Seminars in hematology. 1988 ; Vol. 25, No. 2 Suppl 2. pp. 23-33.
@article{ca537810b7b5472ca05b8eb83611d3f7,
title = "The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma.",
abstract = "The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine (COP-BLAM) programs of combination chemotherapy were administered to patients with advanced diffuse large cell lymphoma. The original COP-BLAM programs were designed to deliver intense multidrug therapy maximizing tumor kill. COP-BLAM programs IA and IB, easily administered on an outpatient basis, produced identical 73{\%} complete remissions (CRs) and 55{\%} long-term, disease-free survival (DFS). COP-BLAM III, an outgrowth of studies using infusional therapy, differed from COP-BLAM by using infusional bleomycin and vincristine alternated with bolus vincristine. With COP-BLAM III, 84{\%} CRs, 76{\%} {"}potential cures,{"} and a 65{\%} DFS were produced at a median follow-up time of 50 months. COD-BLAM IV, using four sequential cycles of infusional chemotherapy, high-dose alternating myelosuppressives (doxorubicin, cyclophosphamide), and cycle-active agents (methotrexate, cytarabine, and etoposide) produced 88{\%} CRs, 67{\%} potential cures, and a 64{\%} DFS at a median follow-up of 24 months. COP-BLAM V employs four to six sequential cycles of infusional chemotherapy tailored to the rapidity of response. Preliminary results in patients with high-risk Hodgkin's disease suggest COP-BLAM V may be effective despite the shortened treatment time. In all programs, prognostic factors were critical determinants in the results achieved, particularly age and rapidity of response.",
author = "M. Coleman and Armitage, {James Olen} and M. Gaynor and D. McDermott and Weisenburger, {D. D.} and K. Adler and M. Beshevkin and Silver, {R. T.} and Reisman, {A. M.} and Pasmantier, {M. W.}",
year = "1988",
month = "1",
day = "1",
language = "English (US)",
volume = "25",
pages = "23--33",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "2 Suppl 2",

}

TY - JOUR

T1 - The COP-BLAM programs

T2 - evolving chemotherapy concepts in large cell lymphoma.

AU - Coleman, M.

AU - Armitage, James Olen

AU - Gaynor, M.

AU - McDermott, D.

AU - Weisenburger, D. D.

AU - Adler, K.

AU - Beshevkin, M.

AU - Silver, R. T.

AU - Reisman, A. M.

AU - Pasmantier, M. W.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine (COP-BLAM) programs of combination chemotherapy were administered to patients with advanced diffuse large cell lymphoma. The original COP-BLAM programs were designed to deliver intense multidrug therapy maximizing tumor kill. COP-BLAM programs IA and IB, easily administered on an outpatient basis, produced identical 73% complete remissions (CRs) and 55% long-term, disease-free survival (DFS). COP-BLAM III, an outgrowth of studies using infusional therapy, differed from COP-BLAM by using infusional bleomycin and vincristine alternated with bolus vincristine. With COP-BLAM III, 84% CRs, 76% "potential cures," and a 65% DFS were produced at a median follow-up time of 50 months. COD-BLAM IV, using four sequential cycles of infusional chemotherapy, high-dose alternating myelosuppressives (doxorubicin, cyclophosphamide), and cycle-active agents (methotrexate, cytarabine, and etoposide) produced 88% CRs, 67% potential cures, and a 64% DFS at a median follow-up of 24 months. COP-BLAM V employs four to six sequential cycles of infusional chemotherapy tailored to the rapidity of response. Preliminary results in patients with high-risk Hodgkin's disease suggest COP-BLAM V may be effective despite the shortened treatment time. In all programs, prognostic factors were critical determinants in the results achieved, particularly age and rapidity of response.

AB - The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine (COP-BLAM) programs of combination chemotherapy were administered to patients with advanced diffuse large cell lymphoma. The original COP-BLAM programs were designed to deliver intense multidrug therapy maximizing tumor kill. COP-BLAM programs IA and IB, easily administered on an outpatient basis, produced identical 73% complete remissions (CRs) and 55% long-term, disease-free survival (DFS). COP-BLAM III, an outgrowth of studies using infusional therapy, differed from COP-BLAM by using infusional bleomycin and vincristine alternated with bolus vincristine. With COP-BLAM III, 84% CRs, 76% "potential cures," and a 65% DFS were produced at a median follow-up time of 50 months. COD-BLAM IV, using four sequential cycles of infusional chemotherapy, high-dose alternating myelosuppressives (doxorubicin, cyclophosphamide), and cycle-active agents (methotrexate, cytarabine, and etoposide) produced 88% CRs, 67% potential cures, and a 64% DFS at a median follow-up of 24 months. COP-BLAM V employs four to six sequential cycles of infusional chemotherapy tailored to the rapidity of response. Preliminary results in patients with high-risk Hodgkin's disease suggest COP-BLAM V may be effective despite the shortened treatment time. In all programs, prognostic factors were critical determinants in the results achieved, particularly age and rapidity of response.

UR - http://www.scopus.com/inward/record.url?scp=0023988254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023988254&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 23

EP - 33

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 2 Suppl 2

ER -